In a recent study posted to the medRxiv* preprint server, researchers assessed the immunogenicity and safety of a fourth homologous boost dose of a recombinant severe acute respiratory syndrome ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback